


SYSTEM FOR CONTROLLED ADMINISTRATION OF A SUBSTANCE FROM A HUMAN -BODY-IMPLANTED INFUSION DEVICE



DESCRIPTION:


The system is a Non-invasive organ refilling device based on ingestible capsules and capable to deliver proper amount of a substance in response to particular registered parameter.

ADVANTAGES:

- Implant of a docking/refilling mechatronic station surgically interfaced with the stomach/duodenum wall. Smart sensorized ingestible capsules acting as insulin cargos along the gastrointestinal tract. Combination of mechatronic/robotic technologies and materials science procedures.

APPLICATIONS:

- The device is expected to have a dramatic impact on diabetes market. 346 million people worldwide have diabetes, and diabetes deaths are expected to double between 2005 and 2030. The market size of the device is estimated in at least 440 M€ yearly (the 20% of current global type 1 diabetes market).



Intellectual properties:

Patent application “System for controlled administration of a substance from a human-body-implanted infusion device”

publication number: [WO2012011132](https://patents.google.com/patent/WO2012011132)